Nuwellis (NASDAQ:NUWE – Get Free Report) was upgraded by equities research analysts at Roth Capital to a “strong-buy” rating in a report released on Monday, Zacks.com reports.
Separately, Roth Mkm assumed coverage on Nuwellis in a report on Monday. They issued a “buy” rating and a $17.00 price target for the company.
Read Our Latest Stock Analysis on Nuwellis
Nuwellis Trading Down 2.1 %
Nuwellis (NASDAQ:NUWE – Get Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($21.00) EPS for the quarter. The firm had revenue of $1.86 million for the quarter. Nuwellis had a negative return on equity of 316.90% and a negative net margin of 202.97%.
Nuwellis Company Profile
Nuwellis, Inc, a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics.
Read More
- Five stocks we like better than Nuwellis
- Roth IRA Calculator: Calculate Your Potential Returns
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- What Are the U.K. Market Holidays? How to Invest and Trade
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- When to Sell a Stock for Profit or Loss
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.